ライフサイエンスコーパス: Taxol

1 as well as clinical paclitaxel formulation (Taxol).

2 of antitumoral agents including paclitaxel (Taxol).

3 nfer resistance to antitumoral drugs such as Taxol.

4 in and mitoxantrone significantly but not to taxol.

5 s axons from degeneration in the presence of taxol.

6 response of cells to the microtubule poison Taxol.

7 Mcl-1 abundance, sensitizing cancer cells to Taxol.

8 h specific mitotic stress stimuli, including taxol.

9 sons, including nocodazole, vincristine, and Taxol.

10 mpaired by depletion of soluble tubulin with taxol.

11 43, both of which sensitized cancer cells to Taxol.

12 ptosis and led to an increased resistance to Taxol.

13 ll uptake of immunotoxin by combination with Taxol.

14 MCAK and the mitotic checkpoint response to taxol.

15 ficient cells have a compromised response to Taxol.

16 t compromising the cytotoxic activity of the taxol.

17 well-established antimitotic agents such as taxol.

18 otubules are absent but not against low dose taxol.

19 or therapeutic efficacy than that of NCM and Taxol.

20 dazole treatment but an impaired response to Taxol.

21 ents (MSAs) and in human tumors resistant to Taxol.

22 bound the least amount of 2-(m-azidobenzoyl)taxol.

23 tive and PTEN-negative glioblastoma cells to Taxol.

24 n A172 cells only after treatment with 50 nM Taxol.

25 ly even in the presence of the MT stabilizer taxol.

26 n exposed to OA or cycloheximide, but not by Taxol.

27 I(SOC) that was abolished by nocodozole and taxol.

28 icient cells exhibit increased resistance to taxol.

29 e source of the anti-cancer diterpenoid drug Taxol.

30 doubled the maximum tolerated dose (MTD) of Taxol.

31 les and microtubules stabilized by GMPCPP or Taxol.

32 n and chemoresistance of MDA-MB-231 cells to Taxol.

33 e and is inhibited by anticancer agents like Taxol.

34 to the level of fame justifiably accorded to Taxol (1) and its chemical siblings.

35 lators such as paclitaxel (originally called taxol; 1 muM), vinblastine (1 and 10 muM), colchicine (1

36 ds (1982), calicheamicin gamma(1)(I) (1992), Taxol (1994), and brevetoxin B (1995).

37 cation of Drosophila larvae with paclitaxel (taxol), a chemotherapeutic agent that causes neuropathy

38 dase, but had limited effect on retention of Taxol, a 14-nm micelle form of PTX.

39 etic screen for mediators of the response to Taxol, a chemotherapeutic agent that stabilizes microtub

40 es; thus we evaluated it in combination with Taxol, a chemotherapeutic with activity in both diseases

41 Taxol, a first-line anti-tumour drug, has low effectiven

42 versely, SDS patient cells were resistant to taxol, a microtubule stabilizing agent.

43 simulations indicated that the frequency of Taxol-accommodating conformations decreased dramatically

44 ults, we conclude that prolonged exposure to Taxol activates mu-calpain, which leads to the degradati

45 m a biomedical perspective to understand how Taxol added to these systems affects the mechanical prop

46 ge-scale molecular simulations, we show that Taxol affects the interactions between the M and H1-S2 l

47 e treated with the BrP-LPA alone (10 mg/kg), Taxol alone (10 mg/kg), or Taxol followed by BrP-LPA.

48 tium-labeled Taxol analog, 2-(m-azidobenzoyl)taxol, alone or in the presence of MSAs.

49 ttranslational modifications of tubulin with taxol also allows integrins into the proximal axon.

50 ization of microtubules by prior exposure to taxol also prevented the formation of DVs, consistent wi

51 ally important for the chemotherapeutic drug Taxol, an important anticancer agent and the only known

52 ifically photolabeled with a tritium-labeled Taxol analog, 2-(m-azidobenzoyl)taxol, alone or in the p

53 esistance to the chemotherapeutic compounds, Taxol and Actinomycin D, but higher susceptibility to th

54 We call microtubules in the presence of Taxol and another stabilizer, doubly stabilized.

55 rs, outperforming commercial paclitaxel drug Taxol and Cremophor EL formulated SB-T-1214.

56 Taxol and dimethyl sulfoxide promote rapid polymerizatio

57 information on the conformational effects of Taxol and discodermolide on microtubules isolated from c

58 ndicate complementary stabilizing effects of Taxol and discodermolide on the microtubules, which may

59 t cells ultimately satisfy the checkpoint in Taxol and do so faster at concentrations >0.5 microM.

60 Examples of high-value diterpenes are taxol and forskolin pharmaceuticals or ambroxide fragran

61 lymerization; unstable GDP-bound; and stable Taxol and GDP-bound.

62 Currently, cost-efficient production of Taxol and its analogs remains limited.

63 as observed against drug-resistant lung-A549/taxol and mammary-MCF-7/Adr xenografts.

64 on differentiation, was in fact increased by taxol and nocodazole and normal in DW12.

65 zation and inhibition of MTs by low doses of taxol and nocodazole enhance and impair spine formation

66 Taxol and other antimitotic agents are frontline chemoth

67 Patients with Taxol and platinum-refractory recurrent ovarian cancer a

68 principle has come mainly from studies using taxol and related drugs to pharmacologically stabilize m

69 sitivity to the antiproliferative effects of Taxol and the FTI lonafarnib when used either as single

70 atment increased resistance of PC-3 cells to Taxol and vinblastine, as assessed by viability and clon

71 Microtubule-targeted agents such as Taxol and vincristine are prescribed widely for various

72 by examining the response of these cells to Taxol and Vinorelbine.

73 shed sensitivity to conventional agents (eg, Taxol and VP-16) but significantly increased susceptibil

74 of MTs stabilized by the taxane-site binders Taxol and zampanolide, and by peloruside, which targets

75 utic drugs (e.g. doxorubicin and paclitaxel (Taxol)) and chemoresistance in these tumor cells.

76 with a new fluorescent taxol donor, TAMRA-X-taxol, and kinesin derivatives with an acceptor fluoroph

77 inical evaluation of MV-NIS in patients with taxol- and platinum-resistant ovarian cancer.

78 At higher levels of Taxol, APC-deficient cells arrest as efficiently as wild

79 non-pathogenic fungi (endophytes) synthesize Taxol, apparently redundantly [2-7].

80 anisms underlying cancer cells resistance to Taxol are not fully understood.

81 However, the working mechanisms for Taxol are not fully understood.

82 bule-stabilizing agents, such as paclitaxel (Taxol), are effective chemotherapy drugs for treating ma

83 Here, using Taxol as a model system, we use nature's favored oxygena

84 ntibodies improved response to platinum- and Taxol-based chemotherapy.

85 in the HA gel), whereas Taxol-gel and other Taxol-based formulations left negligible amount of PTX i

86 not further decrease the tumor burdens than Taxol-based formulations, presumably due to the limited

87 ol (MAQC) data sets and pretreatment data on Taxol-based neoadjuvant breast cancer therapy from multi

88 ntually develop some degree of resistance to Taxol-based therapy.

89 More importantly, we demonstrate that Taxol binding leads to a significant increase in the dyn

90 is of the sequences of beta-tubulin near the Taxol binding site indicated that, in addition to the M-

91 uside overrides the heterogeneity induced by Taxol binding.

92 mation on the structure of microtubules upon Taxol binding.

93 to a region of FtsZ that is analogous to the Taxol-binding site of tubulin.

94 The first committed step of Taxol biosynthesis in the Pacific yew (Taxus brevifolia)

95 We also engineered the next step in Taxol biosynthesis, a P450-mediated 5alpha-oxidation of

96 er Taxus acyltransferases on the paclitaxel (Taxol) biosynthetic pathway and one additional Taxus-der

97 xel, which is purportedly on the paclitaxel (Taxol) biosynthetic pathway.

98 We found that PB-Gly-Taxol bound the target protein beta-tubulin with both hi

99 and that mu-calpain activity is increased in Taxol but not vehicle-treated cells.

100 d in feathers treated with 5-fluorouracil or taxol but not with doxorubicin or arabinofuranosyl cytid

101 are sufficient for a robust response against taxol, but cannot trigger CPC transfer from the chromoso

102 The significant reduction in SAC response to Taxol, but not nocodazole, coupled with the reduced bind

103 delay when spindle function is disrupted by taxol, but not when microtubules are completely depolyme

104 tumor-bearing mice significantly better than Taxol, but PPT-gel did not.

105 Taxol C and paclitaxel were sequentially silylated at th

106 oped for the methylation of the C3' amide of taxol C and paclitaxel.

107 oundation for an eventual total synthesis of Taxol capable of delivering not only the natural product

108 Pretreatment of wild-type platelets with taxol caused microtubule stabilization and phenocopied t

109 d the proliferation in HEY, A2780, and A2780/Taxol cells as evidenced by 3-(4,5-dimethylthiazol-2-yl)

110 Taxol chemotherapy is one of the few therapeutic options

111 vels in mammary tumors following paclitaxel (Taxol) chemotherapy.

112 y was to investigate the treatment effect of Taxol combined with Kanglaite on colorectal cancer cell

113 hibitors we studied the relationship between Taxol concentration, the DM, and the mitotic checkpoint.

114 ls are more sensitive to lower versus higher Taxol concentrations.

115 NMR and synthetic studies established the T-taxol conformation as the bioactive tubulin-binding conf

116 ity to whether or not they could adopt the T-taxol conformation.

117 It is significant that the ability of the Taxol conjugates to overcome Taxol resistance is observe

118 the methods developed, we demonstrated that Taxol could improve SS1P penetration into tumors in para

119 r agents is an effective strategy to enhance Taxol cytotoxicity.

120 growth cones, very much like treatment with Taxol, demonstrating a potential link between MT dynamic

121 a), the hydrogelator (5b), and hydrogel of a taxol derivative without compromising the cytotoxic acti

122 Taxol did not cause upregulation of vascular endothelial

123 We confirmed that, like Taxol, discodermolide binds to the taxane binding pocket

124 rase II (Topo II) drugs, whereas paclitaxel (Taxol) does not have this effect.

125 otubules were labeled with a new fluorescent taxol donor, TAMRA-X-taxol, and kinesin derivatives with

126 he choice of a drug-eluting stent (limus- vs taxol-eluting) in ITDM is controversial, with studies sh

127 The anticancer drug paclitaxel (Taxol) exhibits paradoxical and poorly understood effect

128 alone (10 mg/kg), Taxol alone (10 mg/kg), or Taxol followed by BrP-LPA.

129 osis after treatment with different doses of Taxol for 24 h.

130 -positive) and A172 (PTEN-negative) cells to Taxol for induction of apoptosis.

131 S-O and SJSA), similar to the pharmaceutical Taxol formulation.

132 ndustrial value as biobased pharmaceuticals (taxol), fragrances (sclareol), food additives (steviosid

133 ng to C-5, C-10, and C-13) required to reach Taxol from taxadiene were accomplished.

134 culate PTX entrapped in the HA gel), whereas Taxol-gel and other Taxol-based formulations left neglig

135 Taxol (generic name paclitaxel) is a microtubule-stabili

136 reated with different stabilizers, including Taxol, guanosine-5' [(alpha, beta)-methyleno] triphospha

137 ctionalized intermediate in the synthesis of Taxol has been synthesized, which features the tricyclic

138 rigger PCD, alleviation of SI-induced PCD by taxol implicates a role for microtubule depolymerization

139 cy in suppressing tumor growth than clinical Taxol in a murine 4T1 breast cancer model, owing to prol

140 d a subsequent increase in the resistance to Taxol in cancer cells.

141 silvestrol, has shown activity comparable to taxol in certain settings.

142 zed, FOXO1-mediated, AR-inhibitory effect of Taxol in CRPC cells that may play an important role in T

143 The fungus sequesters Taxol in intracellular hydrophobic bodies that are induc

144 sistance to the microtubule-stabilizing drug Taxol in narrow confinement.

145 particles was over 9-fold lower than that of Taxol in P-gp-overexpressing cells.

146 ed tumor burden, and BrP-LPA was superior to Taxol in reducing blood vessel density in tumors.

147 eficiency compromises the arrest response to Taxol in vivo.

148 it the transport of radiolabeled paclitaxel (Taxol) in MCF-7/DX1 cells, and it completely reversed th

149 increased many cellular variations caused by Taxol, including tubulin polymerization, caspase-3 cleav

150 At subpharmacologic doses, Taxol increased the amount of ISMMC by three to four tim

151 rotubules pharmacologically with paclitaxel (Taxol) increases pyroptosis without affecting the other

152 After treatment with Taxol, increases in p-Akt and VEGF could maintain surviv

153 -sensitizes Snail-expressing cancer cells to Taxol, indicating that miR-125b is critical in Snail-ind

154 On a total protein basis, Taxol induced ISMMC, expanded more CD8(+) cells, activat

155 Paclitaxel (Taxol)-induced cell death requires the intrinsic cell de

156 Down-regulation of Bak1 suppressed Taxol-induced apoptosis and led to an increased resistan

157 Taxol-induced axonal degeneration in Drosophila shares m

158 that a pan-MLK inhibitor (CEP-11004) limited Taxol-induced cell death and that E(2) accentuated this

159 xpression of survivin-2B sensitizes cells to taxol-induced cell growth inhibition and cell death, whi

160 istant cells, causing a marked inhibition of Taxol-induced cytotoxicity and apoptosis and a subsequen

161 Thalidomide (50.0 mg/kg) reduced taxol-induced mechanical allodynia and hyperalgesia wher

162 for effects in preventing the development of taxol-induced mechanical and thermal hyperalgesia in rat

163 sia whereas minocycline (20.0 mg/kg) reduced taxol-induced mechanical hyperalgesia and allodynia as w

164 roteins in the cellular pathway that lead to Taxol-induced peripheral neuropathy, neuronal calcium se

165 ribed approach to understanding and treating Taxol-induced peripheral neuropathy.

166 anical hyperalgesia and allodynia as well as taxol-induced thermal hyperalgesia.

167 sin-expressing macrophages protected against Taxol-induced tumor cell death in coculture, an effect f

168 Prolonged treatment with Taxol induces activation of calpain, degradation of NCS-

169 that the widely used chemotherapeutic agent Taxol, ineffective against Taxol-resistant human ovarian

170 ent, as well as microtubule stabilization by taxol, inhibited host cell invasion by UPEC, as did sile

171 Taxol inhibits most of these conformational changes, all

172 ization of microtubules by pretreatment with Taxol inhibits osteoblast differentiation.

173 ing titers of taxadiene--the first committed Taxol intermediate--approximately 1 gram per liter (~15,

174 emotherapeutic agents, including paclitaxel (Taxol), involve pro-apoptotic ceramide in their anticanc

175 Taxol is a commonly used antitumor agent that hyperstabi

176 Taxol is a plant-derived anti-cancer agent, which has be

177 ggests that the failed arrest in response to Taxol is because of a specific defect in microtubule sta

178 riments determined that the binding site for Taxol is in a hydrophobic pocket in beta-tubulin, little

179 Second, since Taxol is often added to a number of cell types for thera

180 Paclitaxel (Taxol) is a well established chemotherapeutic agent for

181 Paclitaxel (Taxol) is an effective chemotherapeutic agent for treatm

182 Paclitaxel (Taxol) is one of the most effective treatment options fo

183 The prototype of this group of drugs, Taxol, is an effective chemotherapeutic agent used exten

184 lar stabilization of syntelic attachments by Taxol itself appears responsible for accelerated checkpo

185 ues and a scalable laboratory preparation of Taxol itself.

186 B (2), isolaulimalide and laulimalide, have taxol-like microtubule-stabilizing activity, and the lat

187 low cytometry, we synthesized derivatives of Taxol linked to the drug-like fluorophore Pacific Blue (

188 Stabilizing the microtubules with taxol maintained the undulating geometry after injury bu

189 to therapeutic doses of the anticancer agent Taxol, making it an attractive novel therapeutic cancer

190 RPC cells that may play an important role in Taxol-mediated inhibition of CRPC growth.

191 colocalization with tubulin is enhanced upon Taxol-mediated microtubule stabilization, which, togethe

192 As a single chemotherapy, Taxol might be more efficacious in PTEN-positive gliobla

193 o uncouple the reorganizations, we have used taxol, nocodazole, and the specific GSK3-beta inhibitor

194 fter they were arrested in prometaphase with taxol, nocodazole, vincristine, or monastrol.

195 aite pretreatment may increase the effect of Taxol on colorectal cancer.

196 a mechanistic rationale to combine SS1P with Taxol or another cytotoxic drug as a strategy to increas

197 le disrupting agent including nocodazole and taxol or release of mitotic shake-off cells into fresh m

198 o neuroblastoma cells that were treated with Taxol or vincristine inhibited activation of calpain and

199 In contrast, binding of either Taxol or zampanolide induces MT heterogeneity.

200 The attachment of a therapeutic agent (e.g., taxol) or a fluorophore (e.g., 4-nitro-2,1,3-benzoxadiaz

201 G as cells arrest in response to nocodazole, taxol, or monastrol treatments.

202 ful effort to replicate the beginning of the Taxol oxidase phase in the laboratory is reported, culmi

203 ized semisynthetic routes to next generation Taxol (paclitaxel) compounds could conceivably shorten t

204 Taxol (paclitaxel) is a potent anticancer drug first iso

205 so provides a plausible combination therapy, Taxol (Paclitaxel) plus Sorafenib, which was shown to be

206 depletion of protein Daxx increases cellular taxol (paclitaxel) resistance-a common trait of patients

207 Our studies further showed that taxol (paclitaxel) treatment of cancer cells not only up

208 ver 350 members, the most famous of which is Taxol (paclitaxel), a billion-dollar anticancer drug.

209 of this family is the polycyclic diterpenoid Taxol (paclitaxel), which promotes tubulin polymerizatio

210 amous for production of the anti-cancer drug Taxol (paclitaxel).

211 The important anticancer drug Taxol (paclitaxel, PTX) owes its unique activity to its

212 The antimitotic anti-cancer drugs, including taxol, perturb spindle dynamics, and induce prolonged, s

213 bule stabilizer paclitaxel (originally named taxol) precluded microplaque formation.

214 Here we show that a Taxol-producing fungal endophyte, Paraconiothyrium SSM00

215 provide a novel conceptual framework for how Taxol prolongs mitosis and caution against using it in c

216 Finally, we report that Paclitaxel/taxol promotes mitotic rounding and subsequent entosis,

217 rior anticancer efficacy to the conventional Taxol(R) formulation, but with significantly reduced sid

218 nd PTX, represents a superior replacement of Taxol(R) that mitigates the side effects associated with

219 hemotherapeutic drugs, including paclitaxel (Taxol(R)) and vincristine.

220 rmulating PTX with Cremophor EL and ethanol (Taxol(R)) realized its clinical potential, but the formu

221 the conventional solubilization formulation (Taxol(R)), but yielded less toxicity as indicated by the

222 Interestingly, the Taxol((R)) formulation showed higher antitumor activity

223 In comparison, treatment with Taxol((R)) resulted in toxicity issues as body weight de

224 in 1 (XCLASP1) or treatment with the MT drug Taxol reduced axon outgrowth in spinal cord neurons.

225 of TRAIL to either nocodazole or paclitaxel (Taxol) reduced levels of the mitotic checkpoint proteins

226 ilization of midzone MTs with low amounts of Taxol rescues cytokinesis in INCENP actin-binding mutant

227 , the interaction between the development of Taxol resistance and miRNA has not been previously explo

228 ment of targeted therapeutics for overcoming Taxol resistance in a number of different tumor histolog

229 f1 elevates cyclin B stability and increases taxol resistance in cells and mouse xenograft models.

230 ability of the Taxol conjugates to overcome Taxol resistance is observed both in cell culture and in

231 rt a central role for miR-125b in conferring Taxol resistance through the suppression of Bak1 express

232 xol sensitivity, overcoming miR-125-mediated Taxol resistance.

233 gated the role and mechanisms of miR-125b in Taxol resistance.

234 mpare the differentially expressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells

235 1, miR-222, and miR-923 were up-regulated in Taxol-resistant cancer cells by real-time PCR.

236 ctivated after antitubulin drug treatment in taxol-resistant cancer cells.

237 conjugate that is effective against the same Taxol-resistant cell lines.

238 We found that miR-125b was up-regulated in Taxol-resistant cells, causing a marked inhibition of Ta

239 therapeutic agent Taxol, ineffective against Taxol-resistant human ovarian cancer cell lines, can be

240 Further investigation of Daxx-mediated taxol response revealed that Daxx is important for the p

241 ving a possible relationship to platinum and taxol response.

242 siRNA sensitized B16F10 cells to paclitaxel (Taxol), resulting in a complete inhibition of tumor grow

243 xpressed miRNAs in Taxol-resistant and their Taxol-sensitive parental cells.

244 1 in miR-125b-overexpressing cells recovered Taxol sensitivity, overcoming miR-125-mediated Taxol res

245 the oncogenic transcription factor Myc as a taxol sensitizer.

246 SMMC and identification of adducts formed by Taxol should be important for developing molecular cance

247 We show that when treated with Taxol, slippage-resistant HT29 colon carcinoma cells dis

248 Taxol slowed this loss by preventing tubulin depolymeriz

249 We also observed a Taxol-specific reduction in neuronal calcium sensor 1 (N

250 rotubules and prevented stomatal opening and taxol stabilized guard-cell microtubules and delayed sto

251 Bundles of taxol-stabilized microtubules (MTs)--hollow tubules comp

252 s region of the C-terminus of Nup98 and both Taxol-stabilized microtubules and the microtubule-depoly

253 nity of any fluorescently tagged protein for taxol-stabilized microtubules can be measured with this

254 Previous study of self-organization of Taxol-stabilized microtubules into asters in Xenopus mei

255 hods to determine the persistence lengths of taxol-stabilized microtubules.

256 Strikingly, we found that Taxol-stabilized MTs promote Tau filament formation with

257 em tau isoforms on the assembly structure of taxol-stabilized MTs.

258 h from straight to curved in the constituent taxol-stabilized tubulin oligomers, and the structure of

259 acts as an enhancer of depolymerization for taxol-stabilized tubulin.

260 ever, the exact molecular mechanism by which Taxol stabilizes microtubules has remained elusive.

261 lase, HDAC6, or stabilizing microtubules via Taxol stimulates IL-10 hyper-induction.

262 Importantly, this dose of Taxol strongly suppresses intestinal tumourigenesis in m

263 ibited in the presence of nocodazole but not taxol, suggesting that intact, but not dynamic, microtub

264 These endophytes, as well as pure Taxol, suppress fungal pathogens including wood-decaying

265 cycloheximide, or the chemotherapeutic drug Taxol suppressed HBC cell growth.

266 From menthol to cholesterol to Taxol, terpenes are a ubiquitous group of molecules (ove

267 why the duration of mitosis (DM) is less in Taxol than in nocodazole or Eg5 inhibitors we studied th

268 rapeutics, such as rigosertib and paclitaxel/Taxol, that activate JNK through mitotic and oxidative s

269 nd that unlike for other spindle poisons, in Taxol the DM becomes progressively shorter as the concen

270 e stabilization mechanism similar to that of taxol, the epothilones offer a major potential therapeut

271 The ability of Taxol to alter microtubule formation was unchanged by th

272 dition to a combined therapy of (90)Y-B3 and taxol to enhance the synergistic effect.

273 n synergizes with the chemotherapeutic agent taxol to increase mitotic death, demonstrating that STAR

274 mately 1000-fold and reduces the toxicity of Taxol towards cancer cell lines by over 200-fold.

275 lso found in peripheral neuronal tissue from Taxol treated animals.

276 is believed to arrest mitotic progression in taxol-treated cells.

277 wide small interfering RNA (siRNA) screen in taxol-treated HeLa cells, we systematically identify com

278 Inhibiting the aurora-B kinase in Taxol-treated RPE1 cells accelerates checkpoint satisfac

279 In Drosophila, taxol treatment causes swelling, fragmentation, and loss

280 Stabilization of microtubules by taxol treatment did not stop elongation of cytochalasin

281 e AR repression gene maspin, suggesting that Taxol treatment inhibits AR activity.

282 on, detyrosination, and polyglutamylation by Taxol treatment or inhibition of glycogen synthase kinas

283 efect in microtubule stabilization following Taxol treatment rather than a general role of the APC pr

284 Kanglaite pretreatment followed by Taxol treatment was found to show the best synergism amo

285 After Taxol treatment, Nek4 promoted microtubule outgrowth, wh

286 When the forces are weakened by taxol treatment, the outer kinetochore expands radially

287 The effect was phenocopied by taxol treatment.

288 in-2B-specific siRNA made cells resistant to taxol treatment.

289 Senescence occurred following cisplatin- or Taxol-treatment in cell lines from both cancer types and

290 Microtubule perturbation by taxol (TX) and other microtubule-targeting drugs stalls

291 he M-loop in lateral stability in absence of taxol was shown to be minor.

292 8 days; P < .001), use of anthracyclines and taxols was lower (3.7% vs 5.0%; P < .001), and breast-co

293 ells was unaffected following treatment with Taxol, whereas the viability of D54 cells was reduced by

294 However, as opposed to Taxol, which has major interactions with the M-loop, dis

295 Treatment with taxol, which suppresses microtubule dynamics and activat

296 red in LN18 cells after treatment with 25 nM Taxol, while in A172 cells only after treatment with 50

297 First, we ask whether Taxol will combine additively with another stabilizer or

298 By covalently connecting taxol with a motif that is prone to self-assemble, we su

299 Combining Taxol with cathepsin inhibition in vivo significantly en

300 The interaction of Taxol with tubulin and the microtubule has been studied